Drug intelligence / Profile preview

ADMERCIN

Development stage: Preclinical
Lead developer: S2Medical
Modality: Peptides
Administration: Topical

Overview

ADMERCIN is an antimicrobial peptide (AMP) technology developed by S2Medical AB (S2M). It is designed as a truncated peptide that acts as an 'Electroselective Dispersant' targeting bacterial membranes. The technology is specifically engineered to combat antimicrobial-resistant (AMR) infections, including ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.). ADMERCIN is intended for use in treating chronic and acute wound infections, dermatological conditions, and nosocomial infections involving multidrug-resistant (MDR) or carbapenem-resistant strains. It is currently in the preclinical stage, positioned for co-development or licensing to facilitate clinical translation.

Brand names: ADMERCIN

Beyond the preview

Go deeper on ADMERCIN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADMERCIN.

Explore the full profile